You are here

COVID-19

Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license

Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license

Fierce Pharma

Moderna Therapeutics

Flag link:

The FDA has cleared the first home flu and Covid test — but its maker just declared bankruptcy

The FDA has cleared the first home flu and Covid test — but its maker just declared bankruptcy

Stat

Flag link:

Pfizer and BioNTech file BLA for Omicron-targeting Covid-19 vaccine

Pfizer and BioNTech file BLA for Omicron-targeting Covid-19 vaccine

Endpoints

Flag link:

Cerevel blames Covid for delayed neuroscience studies, says president is leaving

Cerevel blames Covid for delayed neuroscience studies, says president is leaving

Endpoints

Cerevel Therapeutics

Parkinson's Disease

Flag link:

PhRMA official discusses legislative priorities, lessons from the pandemic

PhRMA official discusses legislative priorities, lessons from the pandemic

RAPS.org

Flag link:

Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop

Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop

Motley Fool

Flag link:

'We beg you': Biotechs plead for help and funds to find long COVID treatments

'We beg you': Biotechs plead for help and funds to find long COVID treatments

Fierce Biotech

Flagship Pioneering

Flag link:

Merck’s COVID-19 treatment falls short in prevention study

Merck’s COVID-19 treatment falls short in prevention study

BioPharma Dive

clinical trials

Flag link:

Where Will Moderna Be in 5 Years?

Where Will Moderna Be in 5 Years?

Motley Fool

Moderna Therapeutics

Flag link:

Labcorp forecasts up to 90% fall in COVID testing sales in 2023

Labcorp forecasts up to 90% fall in COVID testing sales in 2023

Yahoo/Reuters

Flag link:

Moderna promises to provide COVID vaccines at no out-of-pocket cost

Moderna promises to provide COVID vaccines at no out-of-pocket cost

Endpoints

Moderna Therapeutics

Flag link:

GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

Fierce Biotech

Vir Biotechnology

Flag link:

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

BioSpace

Clover BioPharmaceuticals

Flag link:

U.S. government to buy 1.5 mln more Novavax COVID vaccine doses

U.S. government to buy 1.5 mln more Novavax COVID vaccine doses

Yahoo/Reuters

federal government

Flag link:

Japan cancels 140M dose order for Novavax Covid vaccine amid 'lower than expected' demand

Japan cancels 140M dose order for Novavax Covid vaccine amid 'lower than expected' demand

Endpoints

Flag link:

Lower COVID sales weigh on AZ in fourth quarter

Lower COVID sales weigh on AZ in fourth quarter

Pharmaphorum

Flag link:

Preparing for next pandemic, Korea's SK pumps $261M into vaccine R&D site

Preparing for next pandemic, Korea's SK pumps $261M into vaccine R&D site

Fierce Biotech

Flag link:

Merck pill linked to new mutations, study says

Merck pill linked to new mutations, study says

Fierce Pharma

Flag link:

FDA axes requirement for positive Covid test before Paxlovid use

FDA axes requirement for positive Covid test before Paxlovid use

Endpoints

Flag link:

Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program

Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program

Fierce Biotech

Gilead Sciences

Matinas BioPharma

Flag link:

Pages